How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Multiple Sclerosis Therapeutics Market
- By Therapeutic Class: Immunomodulators, Immunosuppressants, Monoclonal Antibodies, Corticosteroids, Symptomatic Therapies
- By Route of Administration: Oral, Injectable, Intravenous
- By Disease Course: Relapsing-Remitting MS (RRMS), Primary Progressive MS (PPMS), Secondary Progressive MS (SPMS)
- By Mechanism of Action: Sphingosine 1-Phosphate (S1P) Receptor Modulators, Interferon Beta Agents, Anti-CD20 Monoclonal Antibodies, Fumarates, Natalizumab
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Immunomodulators leads By Therapeutic Class at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 17 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 277 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.164 →
- 11 Company Profiles 17 players: SWOT & benchmarking p.172 →
Full report · locked preview
Everything inside the Multiple Sclerosis Therapeutics Market report
A complete, evidence-based study - 11 chapters and 116 sections covering market size, segmentation across 4 axes, regional analysis and 17 company profiles, forecast to 2033.
Segmentation covered
Therapeutic Class 5
Route of Administration 3
Disease Course 3
Mechanism of Action 5
Companies profiled
Novartis AG
Biogen Inc.
Roche Holding AG
Sanofi S.A.
Merck KGaA
Bayer AG
Teva Pharmaceutical Industries Ltd.
Celgene Corporation (a Bristol-Myers Squibb company)
Alexion Pharmaceuticals
Inc. (now part of AstraZeneca)
Jazz Pharmaceuticals plc
Eisai Co. Ltd.
+5 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
17 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Biogen Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Roche Holding AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Sanofi S.A.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Merck KGaA
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Bayer AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Teva Pharmaceutical Industries Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Celgene Corporation (a Bristol-Myers Squibb company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Alexion Pharmaceuticals
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Inc. (now part of AstraZeneca)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Jazz Pharmaceuticals plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Eisai Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Mylan N.V. (now part of Viatris)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.227 →Genzyme Corporation (a Sanofi company)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Almirall
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →S.A.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →MedDay Pharmaceuticals
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.250 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$10,280M by 2033 · 8.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Immunomodulators52.1
- Immunosuppressants9.6
- Monoclonal Antibodies18.3
- Corticosteroids11.8
- Symptomatic Therapies8.1
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,744M → $3,707M · 9.9%
Europe$1,216M → $2,198M · 7.7%
Asia Pacific$1,110M → $2,280M · 9.4%
Latin America$687.1M → $1,315M · 8.5%
Middle East and Africa$528.6M → $1,131M · 10.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →8.622026
8.632027
8.652028
8.652029
8.672030
8.682031
8.702032
8.702033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Novartis AG19.2
- Biogen Inc.15.6
- Roche Holding AG13.5
- Sanofi S.A.7.6
- Merck KGaA10.0
- Bayer AG6.2
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Therapeutic Class31.8%
Route of Administration14.4%
Disease Course37.8%
Mechanism of Action16.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.9
- Europe20.7
- Asia Pacific21.4
- Latin America12.4
- Middle East and Africa10.6
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Novartis AG | 76 | 82 | 89 | 81 | 95 | 79 | 84 |
| Biogen Inc. | 87 | 72 | 83 | 89 | 73 | 93 | 83 |
| Roche Holding AG | 77 | 74 | 80 | 83 | 72 | 78 | 77 |
| Sanofi S.A. | 75 | 60 | 63 | 66 | 72 | 71 | 68 |
| Merck KGaA | 57 | 57 | 64 | 61 | 64 | 59 | 60 |
| Bayer AG | 58 | 64 | 68 | 65 | 56 | 63 | 62 |
| Teva Pharmaceutical Industries Ltd. | 53 | 60 | 63 | 49 | 56 | 65 | 58 |
| Celgene Corporation (a Bristol-Myers Squibb company) | 41 | 60 | 41 | 44 | 38 | 56 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Novartis AG
- Biogen Inc.
- Roche Holding AG
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Novartis AG | ◐ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Biogen Inc. | ✓ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Roche Holding AG | ◐ | ◐ | ✓ | ✓ | ✓ | ◐ |
| Sanofi S.A. | ✓ | ◐ | − | − | ◐ | ◐ |
| Merck KGaA | ◐ | ◐ | ◐ | ◐ | − | ◐ |
| Bayer AG | − | − | ✓ | ◐ | − | ◐ |
| Teva Pharmaceutical Industries Ltd. | ◐ | ◐ | ◐ | − | − | − |
| Celgene Corporation (a Bristol-Myers Squibb company) | − | − | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Novartis AG84
2Biogen Inc.83
3Roche Holding AG77
4Sanofi S.A.68
5Bayer AG62
6Merck KGaA60
7Teva Pharmaceutical Industries Ltd.58
8Celgene Corporation (a Bristol-Myers Squibb company)47
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Novartis AGBiogen Inc.
Challenger2
Strong scale, closing on the leaders.
Roche Holding AGSanofi S.A.
Contender3
Focused players with pockets of strength.
Merck KGaABayer AGTeva Pharmaceutical Industries Ltd.
Niche1
Specialists in a single segment or region.
Celgene Corporation (a Bristol-Myers Squibb company)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Therapeutic Class in North America, then scale across Multiple Sclerosis Therapeutics Market — a $347M beachhead inside a $6.59B market.
Beachhead (SOM)$347Mobtainable near-term
Serviceable (SAM)$2.40Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Immunomodulators
Best fit — highest urgency & budget in Therapeutic Class.
Economic buyer76 fit
Immunosuppressants
Strong fit — clear ROI and a fast path to value.
End user67 fit
Monoclonal Antibodies
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Therapeutic Class in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Route of Administration & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Disease Course
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel28%
Digital / self-serve20%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Therapeutic Class leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Multiple Sclerosis Therapeutics Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified43%
Sales qualified23%
Evaluation13%
Closed-won6%
$12.6KCAC
$45KLTV
3.6:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Multiple Sclerosis Therapeutics Market is a high-growth opportunity — $9.79B by 2033, compounding at 10.4%.
TAM · 2025$4.45Btoday
TAM · 2033$9.79Bforecast
CAGR10.4%2027–2033
Cumulative$61.3Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$9.79BTotal addressable market
SAM$3.39BServiceable available market
SOM$562MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.4% CAGR
Demand compounds through 2033, outpacing GDP across Therapeutic Class.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Therapeutic Class moving from early to mainstream — durable secular demand.
Consolidation upside
17+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$9.79BLarge & growingTAM by 2033 at 10.4% CAGR
$3.39BServiceable nowreachable with today’s model
$562MBeachhead winobtainable near-term share
17+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$7.64BBear6.7% CAGR
$9.79BBase10.4% CAGR
$12.5BBull13.7% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Route of Administration optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Multiple Sclerosis Therapeutics Market — a $6.75B market by 2033. Plan: grow share from 6.8% to 12.4%.
Market size · 2033$6.75Btotal addressable
Market CAGR10.9%2027–2033
Target share12.4%from 6.8% today
Revenue ambition$837Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.8% | 12.4% | Behind |
| Revenue | $466M | $837M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 35.5% | 40.5% | Ahead |
| Customer retention | 89.0% | 92.7% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Therapeutic Class
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Route of Administration capability
A defensible second engine — invest in Route of Administration to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Therapeutic Class share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Route of Administration
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $117M capacity & capability investment
- Greenlight bolt-on M&A in Route of Administration
- Authorise North America expansion plan
- Fund R&D program for Therapeutic Class leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAt risk
- Input-cost & supply riskBehind
- Regulatory / policy changeAt risk
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Multiple Sclerosis Therapeutics Market conversation — a $9.15B market you can size, segment and defend in minutes.
Market size · 2033$9.15Btotal opportunity
Growth8.1%CAGR to 2033
Addressable buyers1,435+accounts in scope
Typical ROI5.2×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Therapeutic Class
Goal Grow share in Therapeutic Class
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.2×return on cost, year one
< 3 mopayback period
$97K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
17+players profiled in this market
Coverage includes
Novartis AGBiogen Inc.Roche Holding AGSanofi S.A.Merck KGaABayer AGTeva Pharmaceutical Industries Ltd.Celgene Corporation (a Bristol-Myers Squibb company)+9 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Multiple Sclerosis Therapeutics Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Multiple Sclerosis Therapeutics Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Microplate Instrumentation and Supplies Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportMultiple Myeloma Therapeutics Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportMolecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Market
Market size, share, segmentation and regional forecast.
$328M market · 2025 base year
View reportMolecular Clostridium Difficile Diagnostic Equipment Market
Market size, share, segmentation and regional forecast.
$386M market · 2025 base year
View reportMonoclonal Antibody Based Products Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportNanobiotechnology Market
Nanobiotechnology Market is valued at USD 14.6 Billion in 2025 and is expected to reach USD 28.…
$14.6B market · 2025 base year
View reportNeedle-Free Drug Injection Systems Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportNeural Control Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportNext Generation Sequencers Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportNicotine Replacement Therapy (NRT) Products Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportNon Hodgkin Lymphoma (NHL) Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportIndustrial Single Punch Tablet Press Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.